GURUFOCUS.COM » STOCK LIST » USA » NAS » Cullinan Oncology Inc (NAS:CGEM) » Definitions » EV-to-EBIT
Switch to:

Cullinan Oncology (NAS:CGEM) EV-to-EBIT

: 0.38 (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cullinan Oncology's Enterprise Value is $-50.37 Mil. Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-133.88 Mil. Therefore, Cullinan Oncology's EV-to-EBIT for today is 0.38.

The historical rank and industry rank for Cullinan Oncology's EV-to-EBIT or its related term are showing as below:

CGEM' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.56   Med: -4.94   Max: 0.38
Current: 0.38

During the past 4 years, the highest EV-to-EBIT of Cullinan Oncology was 0.38. The lowest was -29.56. And the median was -4.94.

CGEM's EV-to-EBIT is ranked better than
91.03% of 513 companies
in the Biotechnology industry
Industry Median: 3.31 vs CGEM: 0.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cullinan Oncology's Enterprise Value for the quarter that ended in Sep. 2022 was $15.16 Mil. Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-133.88 Mil. Cullinan Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -882.96%.


Cullinan Oncology (NAS:CGEM) EV-to-EBIT Historical Data

The historical data trend for Cullinan Oncology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21
EV-to-EBIT - - - -5.79

Cullinan Oncology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.62 -5.79 -1.53 0.23 -0.11

Cullinan Oncology (NAS:CGEM) EV-to-EBIT Competitive Comparison

For the Biotechnology subindustry, Cullinan Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cullinan Oncology (NAS:CGEM) EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cullinan Oncology's EV-to-EBIT falls into.



Cullinan Oncology EV-to-EBIT Calculation

Cullinan Oncology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-50.374/-133.876
=0.38

Cullinan Oncology's current Enterprise Value is $-50.37 Mil.
Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Oncology  (NAS:CGEM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cullinan Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-133.876/15.16226
=-882.96 %

Cullinan Oncology's Enterprise Value for the quarter that ended in Sep. 2022 was $15.16 Mil.
Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Oncology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cullinan Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Oncology (NAS:CGEM) Business Description

Cullinan Oncology logo
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Executives
Martin Anne-marie director ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142
Jones Jeffrey Alan officer: Chief Medical Officer ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Lampert Mark N 10 percent owner 1 SANSOME ST 30TH FL SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST. 40TH FLOOR SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Ahmed Nadim director, officer: President and CEO C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
F2 Gc, Llc 10 percent owner 8 WEST 38TH STREET SUITE 10018 NEW YORK NY 10018
Trigilio Jeffrey officer: Chief Financial Officer C/O CULLINAN MANAGEMENT, INC. ONE MAIN STREET, SUTIE 520 CAMBRIDGE MA 02142

Cullinan Oncology (NAS:CGEM) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership